Alpha-9 Theranostics Inc.

Based in Canada, Alpha-9 Theranostics Inc. specializes in developing innovative radiopharmaceuticals for cancer treatment, focusing on precision targeting of cancer cells to enhance efficacy and minimize damage to healthy tissues. Alpha-9 Theranostics Inc. was founded in 2018 in Vancouver, Canada, and focuses on the development of targeted radiopharmaceuticals.

The company has raised a total of USD 175. 00 mn across its funding rounds, with the most recent funding, Series C, completed on October 23, 2024. The funding round was co-led by Lightspeed Venture Partners and Ascenta Capital, along with participation from notable investors such as Andreessen Horowitz and General Catalyst Partners. The founder's background details are not provided.

Alpha-9 Theranostics Inc. specializes in developing innovative radiopharmaceuticals aimed at treating cancer with precision. The company’s portfolio includes proprietary molecules that selectively target cancer cells, enhancing treatment efficacy while minimizing damage to healthy tissues. By leveraging a bespoke, iterative approach to optimize critical components such as binders and radioisotopes, Alpha-9's products facilitate faster transitions from research to clinical applications.

Primary customers include healthcare providers, hospitals, and oncology specialists in North America and Europe, addressing the increasing demand for advanced cancer therapies. Alpha-9 Theranostics Inc. generates revenue primarily through strategic partnerships and collaborations with healthcare institutions and pharmaceutical companies in oncology. The business model includes direct sales of radiopharmaceuticals to healthcare providers, as well as B2B transactions with pharmaceutical distributors.

Pricing structures are determined based on specific therapies aimed at unmet medical needs in oncology, with revenue driven by demand for effective cancer treatments supported by clinical trials and regulatory approvals. In October 2024, Alpha-9 Theranostics Inc. raised USD 175. 00 mn in Series C funding, which will be utilized to advance its distinctive pipeline of targeted radiopharmaceuticals through clinical studies across multiple tumors with high unmet patient needs.

The company plans to launch new products targeting specific cancer types and expand its market reach into additional regions within North America and Europe by 2025, aiming to fulfill the growing demand for innovative cancer therapies.